Episode 111: Reviewing ACTRIMS 2024

Episode 110 of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 111, "Reviewing ACTRIMS 2024" features a conversation with Daniel Ontaneda, MD, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine, who sat down to discuss the recently concluded Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum. Ontaneda, program committee vice-chair of the meeting, provided insight on a number of notable sessions and discussions that highlighted the recent advances in the MS field. In addition, he talked about the need to innovate clinical trials, ways to tackle progressive MS, and whether drug trials are truly assessing patients at the right time points. Furthermore, he discussed multi-stage trials, the potential role of Bruton tyrosine kinase (BTK) inhibitors, and how this year's meeting differs from previous ones.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• FDA AdComm to Review Investigational Alzheimer Agent Donanemab and Phase 3 Results
• Amylyx Mulls Over Pulling AMX0035 Following Disappointing Phase 3 PHOENIX Findings
• FDA Issues Complete Response Letter for Long-Acting Form of Glatiramer Acetate for Relapsing Multiple Sclerosis
• Phase 2 PROCEED Trial of PACAP-Targeting Antibody Lu AG09222 in Migraine Announced

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences^®. Check out new content and shows every day, only at medicalworldnews.com

EPISODE BREAKDOWN

• 1:05 – Overviewing sessions from ACTRIMS Forum
• 13:10 – Innovating clinical trial design
• 16:15 – 2023 ACTRIMS vs 2024 ACTRIMS
• 20:20 – Neurology News Minute
• 23:30 – Testing combination approaches for progressive MS
• 26:45 – The impact of timing therapeutic interventions 

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

• Click here for Apple Podcasts
• Click here for Spotify
• Click here for Google Podcasts